Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Tuesday. $73.59 million flowed into the stock on the tick-up and $257.11 million flowed out of the stock on the tick-down, for a money net flow of $183.52 million out of the stock. Of all stocks tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.37 for the day and closed at $36.58

Several equities analysts have issued reports on PFE shares. Jefferies Group reaffirmed a “hold” rating and set a $35.00 price objective on shares of Pfizer in a report on Friday, August 18th. BMO Capital Markets reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, September 6th. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective on the stock. in a report on Wednesday, September 13th. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Tuesday, September 19th. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $38.77.

The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market capitalization of $218,102.86, a price-to-earnings ratio of 14.64, a PEG ratio of 2.58 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the company posted $0.61 earnings per share. The business’s revenue was up .9% on a year-over-year basis. analysts forecast that Pfizer Inc. will post 2.59 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.50%. Pfizer’s payout ratio is currently 79.01%.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares in the company, valued at $4,186,450.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in PFE. Vanguard Group Inc. lifted its position in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares during the period. Franklin Resources Inc. lifted its position in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after acquiring an additional 389,629 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after acquiring an additional 2,028,313 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after acquiring an additional 1,085,437 shares during the period. Hedge funds and other institutional investors own 69.89% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Traders Sell Pfizer (PFE) on Strength (PFE)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/14/traders-sell-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.